Note 17 - Related Party Transactions |
12 Months Ended |
|---|---|
Dec. 31, 2017 | |
| Notes to Financial Statements | |
| Related Party Transactions Disclosure [Text Block] | 17. Related Party TransactionStephen Hoffman is a Senior Advisor to PDL and a member of the Company's Board of Directors, or the Board. The Board was aware of Dr. Hoffman ’s status as an interested party in the Royalty Monetization and Dr. Hoffman recused himself from all deliberations and actions taken by the Board with respect to the Royalty Monetization. Dr. Hoffman’s consulting compensation from PDL is composed, in part, of a success fee which is formula driven based on a minimum dollar value of deals and the total dollar value of the deals, his relative contribution to each of the concluded deals, and the total dollar value deployed in 2015. PDL estimates the amount attributable to the AcelRx transaction in the year ended December 31, 2015 to be approximately $0.3 million. The Company makes royalty payments to PDL in connection with the Royalty Monetization as described in Note 8 “Liability Related to Sale of Future Royalties.” |